{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-24-000121","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.280359+00:00","generated_at":"2026-05-30T02:44:47.355859+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kiora Q3 net loss $3.4M; cash $29M; advancing two Phase 2 retinal trials","bullets":["Cash and equivalents $29.0M at Sept 30, plus $1.8M collaboration receivables; runway into 2027.","Net loss $3.4M vs $5.8M in Q3 2023; decrease due to -$1.1M non-cash change in contingent consideration.","R&D expenses net $1.3M after $0.9M Théa reimbursement; G&A flat at $1.4M.","IND approved for ABACUS-2 Phase 2 study of KIO-301 in retinitis pigmentosa; first patient dosing in 2025.","Phase 2 KLARITY trial of KIO-104 designed; submission for approval on track for Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-24-000121","json":"https://secwatch.observer/filing/0001372514-24-000121.json","markdown":"https://secwatch.observer/filing/0001372514-24-000121.md","text":"https://secwatch.observer/filing/0001372514-24-000121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000121/0001372514-24-000121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000121/kprx-20241108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:44:47.355859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}